By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Saladax Biomedical announced today a collaborative study of metastatic colorectal cancer patients treated with 5-fluorouracil, or 5-FU, and whose doses will be optimized based on actual 5-FU blood levels.

As part of the collaboration with the Central European Society for Anticancer Drug Research, or CESAR, Saladax's My5-FU immunoassay technology will be used to measure 5-FU levels.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.